
Ingrid A Mayer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1507893/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03). Journal of Clinical Oncology, 2022, 40, 449-458.	1.6	25
2	Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). Journal of Clinical Oncology, 2022, 40, 282-293.	1.6	88
3	Abstract P4-10-02: Patient-reported outcomes in EA1131: A randomized phase III trial of platinum vs. capecitabine in patients with residual triple-negative breast cancer after neoadjuvant chemotherapy. Cancer Research, 2022, 82, P4-10-02-P4-10-02.	0.9	1
4	Abstract P3-14-11: Mammaprint and Blueprint identify genomic differences in HR+ HER2- breast cancers from young Black and White women. Cancer Research, 2022, 82, P3-14-11-P3-14-11.	0.9	0
5	Abstract PD13-01: Balixafortide (a CXCR4 antagonist)+eribulin versus eribulin alone in patients with HER2 negative, locally recurrent or metastatic breast cancer: An international, randomized, phase 3 trial (FORTRESS). Cancer Research, 2022, 82, PD13-01-PD13-01.	0.9	1
6	Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. Breast Cancer Research and Treatment, 2022, 195, 127-139.	2.5	15
7	Peripheral Blood Monocyte Abundance Predicts Outcomes in Patients with Breast Cancer. Cancer Research Communications, 2022, 2, 286-292.	1.7	2
8	Effect of Metformin vs Placebo on Invasive Disease–Free Survival in Patients With Breast Cancer. JAMA - Journal of the American Medical Association, 2022, 327, 1963.	7.4	81
9	Hydroxychloroquine as Pre-exposure Prophylaxis for Coronavirus Disease 2019 (COVID-19) in Healthcare Workers: A Randomized Trial. Clinical Infectious Diseases, 2021, 72, e835-e843.	5.8	103
10	Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial. Clinical Breast Cancer, 2021, 21, 80-91.e7.	2.4	140
11	Racial/Ethnic Disparities in All-Cause Mortality among Patients Diagnosed with Triple-Negative Breast Cancer. Cancer Research, 2021, 81, 1163-1170.	0.9	10
12	At the Bedside: Profiling and treating patients with CXCR4-expressing cancers. Journal of Leukocyte Biology, 2021, 109, 953-967.	3.3	15
13	Radiotherapy after breastâ€conserving surgery for elderly patients with earlyâ€stage breast cancer: A national registryâ€based study. International Journal of Cancer, 2021, 148, 857-867.	5.1	2
14	Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer. Clinical Cancer Research, 2021, 27, 3896-3904.	7.0	36
15	Abstract PD11-05: Diabetes decreases overall survival in women with breast cancer in the southern community cohort study. , 2021, , .		1
16	Inhibition of the PI3K/mTOR Pathway in Breast Cancer to Enhance Response to Immune Checkpoint Inhibitors in Breast Cancer. International Journal of Molecular Sciences, 2021, 22, 5207.	4.1	20
17	Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial. Npj Breast Cancer, 2021, 7, 74.	5.2	16
18	Patient-Reported Outcomes in Patients With <i>PIK3CA</i> -Mutated Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer From SOLAR-1. Journal of Clinical Oncology, 2021, 39, 2005-2015.	1.6	23

#	Article	IF	CITATIONS
19	Human and Machine Intelligence Together Drive Drug Repurposing in Rare Diseases. Frontiers in Genetics, 2021, 12, 707836.	2.3	9
20	Cancer Antigen 15-3/Mucin 1â€,Levels in CCTG MA.32: A Breast Cancer Randomized Trial of Metformin vs Placebo. JNCI Cancer Spectrum, 2021, 5, pkab066.	2.9	5
21	Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131. Journal of Clinical Oncology, 2021, 39, 2539-2551.	1.6	78
22	Reply to T. Shimoi et al and Y. Shimanuki et al. Journal of Clinical Oncology, 2021, 39, JCO.21.01905.	1.6	3
23	New targets in endocrine-resistant hormone receptor-positive breast cancer. Clinical Advances in Hematology and Oncology, 2021, 19, 511-521.	0.3	1
24	Sex Disparity Observed for Oncotype DX Breast Recurrence Score in Predicting Mortality Among Patients with Early Stage ER-Positive Breast Cancer. Clinical Cancer Research, 2020, 26, 101-109.	7.0	14
25	Systemic Inflammation After Radiation Predicts Locoregional Recurrence, Progression, and Mortality in Stage II-III Triple-Negative Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2020, 108, 268-276.	0.8	16
26	Correlative studies investigating effects of PI3K inhibition on peripheral leukocytes in metastatic breast cancer: potential implications for immunotherapy. Breast Cancer Research and Treatment, 2020, 184, 357-364.	2.5	5
27	Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer. Drugs, 2020, 80, 1685-1697.	10.9	72
28	Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer. Clinical Cancer Research, 2020, 26, 5668-5681.	7.0	37
29	Disparities in BRCA counseling across providers in a diverse population of young breast cancer survivors. Genetics in Medicine, 2020, 22, 1088-1093.	2.4	10
30	Combining Adjuvant Radiotherapy With Capecitabine in Chemotherapy-resistant Breast Cancer: Feasibility, Safety, and Toxicity. Clinical Breast Cancer, 2020, 20, 344-352.e1.	2.4	11
31	Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with <i>AKT1</i> E17K-Mutant, ER-Positive Metastatic Breast Cancer. Clinical Cancer Research, 2020, 26, 3947-3957.	7.0	54
32	Reciprocal expression of Annexin A6 and RasCRF2 discriminates rapidly growing from invasive triple negative breast cancer subsets. PLoS ONE, 2020, 15, e0231711.	2.5	11
33	Overall Mortality After Diagnosis of Breast Cancer in Men vs Women. JAMA Oncology, 2019, 5, 1589.	7.1	103
34	PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer. Npj Breast Cancer, 2019, 5, 31.	5.2	31
35	Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. New England Journal of Medicine, 2019, 380, 2395-2405.	27.0	349
36	Alpelisib for <i>PIK3CA</i> -Mutated, Hormone Receptor–Positive Advanced Breast Cancer. New England Journal of Medicine, 2019, 380, 1929-1940.	27.0	1,582

#	Article	IF	CITATIONS
37	Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer. Nature Communications, 2019, 10, 1373.	12.8	252
38	Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. New England Journal of Medicine, 2019, 380, 741-751.	27.0	542
39	Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib. Clinical Cancer Research, 2019, 25, 7381-7387.	7.0	13
40	Alpelisib Plus Fulvestrant in <i>PIK3CA</i> -Altered and <i>PIK3CA</i> -Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer. JAMA Oncology, 2019, 5, e184475.	7.1	187
41	<i>PIK3CA</i> C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3K α Inhibitors. Clinical Cancer Research, 2018, 24, 1426-1435.	7.0	27
42	Motivation for Launching a Cancer Metastasis Inhibition (CMI) Program. Targeted Oncology, 2018, 13, 61-68.	3.6	8
43	Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node–Positive and High-Risk Lymph Node–Negative Breast Cancer (E5103). Journal of Clinical Oncology, 2018, 36, 2621-2629.	1.6	52
44	Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial. Journal of Clinical Oncology, 2018, 36, 3126-3133.	1.6	52
45	A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer. Breast Cancer Research, 2018, 20, 109.	5.0	48
46	Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. New England Journal of Medicine, 2018, 379, 111-121.	27.0	1,558
47	Effects of metformin versus placebo on vitamin B12 metabolism in non-diabetic breast cancer patients in CCTG MA.32. Breast Cancer Research and Treatment, 2017, 164, 371-378.	2.5	9
48	A 3q gene signature associated with triple negative breast cancer organ specific metastasis and response to neoadjuvant chemotherapy. Scientific Reports, 2017, 7, 45828.	3.3	21
49	PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses. Clinical Cancer Research, 2017, 23, 3371-3384.	7.0	80
50	18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials. Clinical Cancer Research, 2017, 23, 3053-3060.	7.0	66
51	Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer. Clinical Cancer Research, 2017, 23, 6138-6150.	7.0	94
52	Genomic profiling of ER ⁺ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. Science Translational Medicine, 2017, 9, .	12.4	91
53	A Case Report of Severe Type B Lactic Acidosis Following First Dose of Nivolumab in a VHL-Mutated Metastatic Renal Cell Carcinoma. Kidney Cancer, 2017, 1, 83-88.	0.4	4
54	Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. Journal of Clinical Oncology, 2017, 35, 2141-2148.	1.6	283

#	Article	IF	CITATIONS
55	The PI3K/AKT Pathway as a Target for Cancer Treatment. Annual Review of Medicine, 2016, 67, 11-28.	12.2	631
56	Breast Cancer, Version 1.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1475-1485.	4.9	134
57	Advanced Hormone-Sensitive Breast Cancer: Overcoming Resistance. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 655-657.	4.9	2
58	Effect of Metformin vs Placebo on and Metabolic Factors in NCIC CTG MA.32. Journal of the National Cancer Institute, 2015, 107, djv006-djv006.	6.3	112
59	Clinical Implications of Mutations in the PI3K Pathway in HER2+ Breast Cancer: Prognostic or Predictive?. Current Breast Cancer Reports, 2015, 7, 210-214.	1.0	5
60	Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2015, 33, 2695-2704.	1.6	279
61	Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [¹⁸ F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003). Iournal of Clinical Oncology, 2015, 33, 2623-2631.	1.6	49
62	Kinome-wide Functional Screen Identifies Role of PLK1 in Hormone-Independent, ER-Positive Breast Cancer. Cancer Research, 2015, 75, 405-414.	0.9	53
63	<i>PIK3CA</i> Activating Mutations: A Discordant Role in Early Versus Advanced Hormone-Dependent Estrogen Receptor–Positive Breast Cancer?. Journal of Clinical Oncology, 2014, 32, 2932-2934.	1.6	32
64	Enabling a Genetically Informed Approach to Cancer Medicine: A Retrospective Evaluation of the Impact of Comprehensive Tumor Profiling Using a Targeted Next-Generation Sequencing Panel. Oncologist, 2014, 19, 616-622.	3.7	94
65	New Strategies for Triple-Negative Breast Cancer—Deciphering the Heterogeneity. Clinical Cancer Research, 2014, 20, 782-790.	7.0	242
66	Molecular Heterogeneity of Triple-Negative Breast Cancer. Current Breast Cancer Reports, 2014, 6, 154-158.	1.0	58
67	Stand Up to Cancer Phase Ib Study of Pan-Phosphoinositide-3-Kinase Inhibitor Buparlisib With Letrozole in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. Journal of Clinical Oncology, 2014, 32, 1202-1209.	1.6	159
68	Bevacizumab (Bv) in the adjuvant treatment of HER2-negative breast cancer: Final results from Eastern Cooperative Oncology Group E5103 Journal of Clinical Oncology, 2014, 32, 500-500.	1.6	38
69	SU2C phase lb study of the PI3Kα inhibitor BYL719 with letrozole in ER+/HER2– metastatic breast cancer (MBC) Journal of Clinical Oncology, 2014, 32, 516-516.	1.6	2
70	Whole-exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients (pts) treated with prior trastuzumab (T): A correlative analysis of TBCRC003 Journal of Clinical Oncology, 2014, 32, 536-536.	1.6	5
71	Prediction and early detection of anthracycline-related cardiotoxicity using cardiac biomarkers Journal of Clinical Oncology, 2014, 32, 9644-9644.	1.6	5
72	Phase II, randomized, placebo-controlled study of BYL719 or buparlisib (BKM120) with letrozole for neoadjuvant treatment of postmenopausal women with HR+/HER2â^', <i>PIK3CA</i> mutant or wild-type, breast cancer (BC) Journal of Clinical Oncology, 2014, 32, TPS655-TPS655.	1.6	1

#	Article	IF	CITATIONS
73	Prevention of stomatitis in patients with hormone receptor–positive advanced breast cancer treated with everolimus plus exemestane: A phase II study of a steroid-based mouthwash Journal of Clinical Oncology, 2014, 32, TPS661-TPS661.	1.6	1
74	Vitamin B12 (Vit B12) biochemical (BCH) deficiency (DEF) in non-diabetic breast cancer (BC) patients on NCIC CTG MA.32: A phase III randomized adjuvant BC trial comparing metformin (Met) to placebo (Pl) Journal of Clinical Oncology, 2014, 32, 542-542.	1.6	1
75	TBCRC028: A phase Ib/II trial of GDC-0941 (a PI3K inhibitor) in combination with cisplatin in metastatic androgen receptor-negative triple-negative breast cancer (TNBC) Journal of Clinical Oncology, 2014, 32, TPS1148-TPS1148.	1.6	1
76	Effect of metformin versus placebo on weight and metabolic factors in initial patients enrolled onto NCIC CTG MA.32, a multicenter adjuvant randomized controlled trial in early-stage breast cancer (BC) Journal of Clinical Oncology, 2013, 31, 1033-1033.	1.6	3
77	Subtyping of triple-negative breast cancer. Clinical Advances in Hematology and Oncology, 2013, 11, 731-2.	0.3	2
78	Discordant Cellular Response to Presurgical Letrozole in Bilateral Synchronous ER+ Breast Cancers with a <i>KRAS</i> Mutation or <i>FGFR1</i> Gene Amplification. Molecular Cancer Therapeutics, 2012, 11, 2301-2305.	4.1	22
79	Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Research and Treatment, 2011, 126, 215-220.	2.5	170